Literature DB >> 15133862

Biochemical and radiological predictors of malignant biliary strictures.

Ibrahim-A Al-Mofleh1, Abdulrahman-M Aljebreen, Saleh-M Al-Amri, Rashed-S Al-Rashed, Faleh-Z Al-Faleh, Hussein-M Al-Freihi, Ayman-A Abdo, Arthur-C Isnani.   

Abstract

AIM: Differentiation of benign biliary strictures (BBS) from malignant biliary strictures (MBS) remains difficult despite improvement in imaging and endoscopic techniques. The aim of this study was to identify the clinical, biochemical and or radiological predictors of malignant biliary strictures.
METHODS: We retrospectively reviewed all charts of patients who had biliary strictures (BS) on endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous cholangiography (PTC) in case of unsuccessful ERCP from March 1998 to August 2002. Patient characteristics, clinical features, biochemical, radiological and biopsy results were all recorded. Stricture etiology was determined based on cytology, biopsy or clinical follow-up. A receiver operator characteristic (ROC) curve was constructed to determine the optimal laboratory diagnostic criterion threshold in predicting MBS.
RESULTS: One hundred twenty six patients with biliary strictures were enrolled, of which 72 were malignant. The mean age for BBS was 53 years compared to 62.4 years for MBS (P=0.0006). Distal bile duct stricture was mainly due to a malignant process 48.6% vs 9% (P=0.001). Alkaline phosphates and AST levels were more significantly elevated in MBS (P=0.0002). ROC curve showed that a bilirubin level of 84 micromol/L or more was the most predictive of MBS with a sensitivity of 98.6%, specificity of 59.3% and a positive likelihood ratio of 2.42 (95% CI=0.649-0.810). Proximal biliary dilatation was more frequently encountered in MBS compared to BBS, 73.8% vs 39.5% (P=0.0001). Majority of BBS (87%) and MBS (78%) were managed endoscopically.
CONCLUSION: A serum bilirubin level of 84 micromol/L or greater is the best predictor of MBS. Older age, proximal biliary dilatation, higher levels of bilirubin, alkaline phosphatase, ALT and AST are all associated with MBS. ERCP is necessary to diagnose and treat benign and malignant biliary strictures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133862      PMCID: PMC4656293          DOI: 10.3748/wjg.v10.i10.1504

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Diagnostic and therapeutic uses of ERCP in pancreatic and biliary tract malignancies.

Authors:  Robert H Hawes
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

Review 2.  CT and magnetic resonance imaging in pancreatic and biliary tract malignancies.

Authors:  Koenraad J Mortele; Hoon Ji; Pablo R Ros
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

3.  Endoscopic retrograde cholangiopancreatographic evaluation of patients with obstructive jaundice.

Authors:  Muhammad Khurram; A A Durrani; Zubair Hasan; Amar ul Ala Butt; Shazia Ashfaq
Journal:  J Coll Physicians Surg Pak       Date:  2003-06       Impact factor: 0.711

4.  Primer on certain elements of medical decision making.

Authors:  B J McNeil; E Keller; S J Adelstein
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Management of benign biliary strictures: biliary enteric anastomosis vs endoscopic stenting.

Authors:  A Tocchi; G Mazzoni; G Liotta; G Costa; L Lepre; M Miccini; E De Masi; M A Lamazza; E Fiori
Journal:  Arch Surg       Date:  2000-02

7.  Bile duct carcinoma without jaundice: clues to early diagnosis.

Authors:  M Sugiyama; Y Atomi; A Kuroda; T Muto
Journal:  Hepatogastroenterology       Date:  1997 Sep-Oct

8.  Tumor vessel: a valuable cholangioscopic clue of malignant biliary stricture.

Authors:  H J Kim; M H Kim; S K Lee; K S Yoo; D W Seo; Y I Min
Journal:  Gastrointest Endosc       Date:  2000-11       Impact factor: 9.427

9.  Magnetic resonance cholangiography: comparison with endoscopic retrograde cholangiopancreatography.

Authors:  J A Soto; M A Barish; E K Yucel; D Siegenberg; J T Ferrucci; R Chuttani
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

10.  Endoscopic retrograde wire-guided cytology of malignant biliary strictures using a novel scraping brush.

Authors:  V K Parasher; K Huibregtse
Journal:  Gastrointest Endosc       Date:  1998-09       Impact factor: 9.427

View more
  13 in total

1.  Total bilirubin is a good discriminator between benign and malignant biliary strictures.

Authors:  Larisa Vasilieva; Alexandra Alexopoulou; Stephanos I Papadhimitriou; Andreas Romanos; Dimitrios Xynopoulos; Spyros P Dourakis
Journal:  HPB (Oxford)       Date:  2011-10-23       Impact factor: 3.647

Review 2.  Endoscopic therapy of benign biliary strictures.

Authors:  Joel R Judah; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

3.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

4.  Bilirubin levels predict malignancy in patients with obstructive jaundice.

Authors:  Giuseppe Garcea; Wee Ngu; Christopher P Neal; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2011-06       Impact factor: 3.647

5.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

6.  Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study.

Authors:  Sundeep Singh Saluja; Raju Sharma; Sujoy Pal; Peush Sahni; Tushar Kanti Chattopadhyay
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Malignant biliary strictures in patients with a normal bilirubin and/or normal liver enzymes.

Authors:  Sarah C Thomasset; David Saunders; Adele Holland; Ashley R Dennison; Giuseppe Garcea
Journal:  HPB (Oxford)       Date:  2015-08-07       Impact factor: 3.647

8.  Is preoperative subclassification of type I choledochal cyst necessary?

Authors:  Kyuwhan Jung; Ho-Seong Han; Jai Young Cho; Yoo-Seok Yoon; Dae-Wook Hwang
Journal:  Korean J Radiol       Date:  2012-04-23       Impact factor: 3.500

9.  Role of biliary tract cytology in the evaluation of extrahepatic cholestatic jaundice.

Authors:  Mamta Gupta; Radha R Pai; Devi Dileep; Sandeep Gopal; Suresh Shenoy
Journal:  J Cytol       Date:  2013-07       Impact factor: 1.000

10.  Detection of benign hilar bile duct stenoses - A retrospective analysis in 250 patients with suspicion of Klatskin tumour.

Authors:  Uwe Scheuermann; Rizky Widyaningsih; Maria Hoppe-Lotichius; Michael Heise; Gerd Otto
Journal:  Ann Med Surg (Lond)       Date:  2016-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.